Company intelligence / Profile preview
OrienGene Biotechnology
Beijing, Beijing, Chinaoriengene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OrienGene's lead program, "OrienX010"—a recombinant human GM-CSF-expressing herpes simplex virus—is in Phase II trials for malignant melanoma. Data from Phase I trials have been presented at major oncology conferences, showing ongoing clinical progress but no published pivotal results yet.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virus therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beijing Bozhiyin T&SSTART Shanghai
Beyond the preview
Go deeper on OrienGene Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OrienGene Biotechnology.